Background: Mucormycosis is an invasive fungal infection. It is rare and commonly associated with fatal outcomes.
Methods: We report two cases of thoracic mucormycosis in immunocompetent patients. First, is an immunocompetent child with mediastinal mass and extension into the pericardium and left atrium. The second is a young woman with a left pulmonary artery pseudoaneurysm.
Results: The first patient could not be salvaged while the second patient was successfully managed with surgical intervention and systemic antifungal treatment.
Conclusion: Mucormycosis should be considered as a differential diagnosis in the management of immunocompetent patients in patients with pyrexia of unknown origin and a mediastinal mass. Early and aggressive surgical management along with systemic antifungal treatment improves the survival in this subset of patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jocs.15332 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
is a common pathogen that causes foodborne illness worldwide. There is limited evidence describing the treatment of gastrointestinal non-typhoidal (NTS). Clinicians are inclined to treat these infections with antibiotics, but the use of antibiotics may paradoxically worsen gastrointestinal symptoms and prolong bacterial stool shedding.
View Article and Find Full Text PDFThe GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration.
J Exp Clin Cancer Res
January 2025
Department of Biology and Biotechnologies "Charles Darwin", Sapienza University, 00185, Rome, Italy.
Background: Metabolic syndrome represents a pancreatic ductal adenocarcinoma (PDAC) risk factor. Metabolic alterations favor PDAC onset, which occurs early upon dysmetabolism. Pancreatic neoplastic lesions evolve within a dense desmoplastic stroma, consisting in abundant extracellular matrix settled by cancer associated fibroblasts (CAFs).
View Article and Find Full Text PDFPeri-Implant Epstein-Barr Virus (+) Mucocutaneous Ulcer in an Immunocompetent Patient: Case Report and Review of the Literature.
Clin Implant Dent Relat Res
February 2025
Department of Stomatology, Research Group GIU21/042, University of the Basque Country/EHU, Leioa, Spain.
Epstein-Barr virus (+) mucocutaneous ulcer (EBVMCU) is an uncommon benign lymphoproliferative lesion that develops in immunocompromised patients. We present a special case of EBVMCU located in the peri-implant mucosa and we review the oral cases published to date. An 88-year-old man with no medical history of interest was attended in the dental clinic due to an ulcerated tumor located in the peri-implant mucosa.
View Article and Find Full Text PDFAn epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models.
J Clin Invest
January 2025
Department of Biochemistry and Molecular Genetics and.
Mutations or homozygous deletions of MHC class II (MHC-II) genes are commonly found in B cell lymphomas that develop in immune-privileged sites and have been associated with patient survival. However, the mechanisms regulating MHC-II expression, particularly through genetic and epigenetic factors, are not yet fully understood. In this study, we identified a key signaling pathway involving the histone H2AK119 deubiquitinase BRCA1 associated protein 1 (BAP1), the interferon regulatory factor interferon regulatory factor 1 (IRF1), and the MHC-II transactivator class II transactivator (CIITA), which directly activates MHC-II gene expression.
View Article and Find Full Text PDFChimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models.
Nat Commun
January 2025
Carisma Therapeutics Inc, Philadelphia, PA, USA.
We previously developed human CAR macrophages (CAR-M) and demonstrated redirection of macrophage anti-tumor function leading to tumor control in immunodeficient xenograft models. Here, we develop clinically relevant fully immunocompetent syngeneic models to evaluate the potential for CAR-M to remodel the tumor microenvironment (TME), induce T cell anti-tumor immunity, and sensitize solid tumors to PD1/PDL1 checkpoint inhibition. In vivo, anti-HER2 CAR-M significantly reduce tumor burden, prolong survival, remodel the TME, increase intratumoral T cell and natural killer (NK) cell infiltration, and induce antigen spreading.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!